Why the study?
Chemotherapy-induced oral hyperpigmentation resulting from anthracycline antibiotics is rare and poorly documented, especially for idarubicin.
Population
A 29-year-old female with high-risk AML
Design
Case report
Key result
Idarubicin-based induction therapy was associated with the development of rare, benign, and reversible tongue hyperpigmentation on day 19 of treatment in a 29-year-old female with AML.
Authors
Loading...
Idarubicin may cause oral hyperpigmentation in AML; this Level 5 case leaves open incidence and clinical relevance.
Case Report (n=1)
Idarubicin-associated tongue hyperpigmentation is a rare, benign, and reversible adverse effect that should be recognized to avoid unnecessary modification of life-saving chemotherapy.
Puttegowda et al. (2026) conducted a case report in Acute myeloid leukemia (AML) (n=1). Idarubicin + cytarabine was evaluated on Tongue hyperpigmentation. Idarubicin-based induction therapy was associated with the development of rare, benign, and reversible tongue hyperpigmentation on day 19 of treatment in a 29-year-old female with AML.